Verrica Pharmaceuticals Inc. (VRCA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.58
- As of
Kresmion compiles this page from VRCA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Verrica Pharmaceuticals Inc. (VRCA): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
See the full VRCA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VRCA on one page. Preview it with sample data, then open it live with a free account.
Preview the VRCA dossierActive signals for VRCA
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 24.9%, EPS $-0.48 vs $-0.3842 estimate
- highINSTITUTIONAL_EXIT
TWO SIGMA INVESTMENTS, LP cut 57% of VRCA (2026Q1)
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 10.7% - EPS $-0.41 vs $-0.3703 estimate
- mediumEARNINGS_MISS
Missed consensus by 10.7% - EPS $-0.41 vs $-0.3703 estimate
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 102.8% - EPS $0.02 vs $-0.7191 estimate
FREE, NO ACCOUNT
Every signal on VRCA, as it fires
You are seeing 5 of 8 signals recorded on VRCA since 2026-05-17.
The five above landed across 5 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VRCA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 92511W207 · 2026Q2 | $250K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92511W207 · 2026Q2 | $133K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VRCA
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VRCA against its peers
VRCA's operating margin of -34.2% ranks in the 72nd percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | VRCA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 35.6M USD | 8.7M USD | 59 | 10 |
| Operating margin | -34.2% | -152.0% | 72 | 8 |
| Net margin | -50.3% | -257.9% | 65 | 9 |
| Return on equity | -72.3% | -89.7% | 56 | 16 |
| 1 year | -12.7% | -26.7% | 71 | 18 |
Peers (21): MNOV, OSTX, GANX, NTHI, MAIA, KZIA, PTHS, CING, ONCY, XBIT, NMRA, ACRV, RNTX, CSBR, EQ, HRTX, FBIO, CRDF, PMN, AARD, CRBP. Left out: OKYO (period gap), HYFT (period gap), TELO (no annual filing), APLM (period gap). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (VRCA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VRCA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VRCA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.